Identifying DNA markers for better follow-up in head and neck cancer
Prognostic Markers for a Better Follow-up in Head and Neck Cancer.
This study is trying to find specific DNA changes in head and neck cancer patients to see if tracking these changes in their blood can help predict how well they will respond to treatment and how long they might live.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Karolinska Institutet Academic / other |
| Locations | 1 site (Stockholm) |
| Trial ID | NCT06094985 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify specific DNA mutations and aberrations in tumors of head and neck cancer patients and track these changes in blood over time. By correlating the presence of these markers with pathological parameters, radiological findings, and tumor stage, the study seeks to predict treatment responses and survival outcomes. The methodology involves DNA exome sequencing of both tumor and blood samples from participants who have undergone surgery for their condition.
Who should consider this trial
Good fit: Ideal candidates for this study are adults diagnosed with head and neck cancer who are undergoing surgical treatment.
Not a fit: Patients who do not consent to participate, are under 18 years old, or do not have tumor material available for sampling may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective follow-up care for patients with head and neck cancer.
How similar studies have performed: While the approach of using DNA markers for monitoring cancer is gaining traction, this specific study's methodology may offer novel insights into head and neck cancer follow-up.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient diagnosed with head and neck cancer * Treatment includes surgery * Consent to participate Exclusion Criteria: * No consent * Age below 18 years * No surgery * No tumor material to sample
Where this trial is running
Stockholm
- Karolinska universitetssjukhuset — Stockholm, Sweden (Recruiting)
Study contacts
- Principal investigator: Anders Näsman, MD PhD — Karolinska institutet and Karolinska Universitetssjukhuset
- Study coordinator: Anders Näsman, MD PhD
- Email: anders.nasman@ki.se
- Phone: +46812370000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.